Ironwood Pharmaceuticals (IRWD) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
9 Jan, 2026Strategic Vision and Restructuring
Focus is shifting to apraglutide for short bowel syndrome, with a rolling NDA submission now expected in Q3 2025 to include robust long-term data from the STARS Extend study.
Workforce reduction of approximately 50%, mainly impacting the field force, aims to streamline operations and support the apraglutide launch, with restructuring charges of $20–$25 million and annual operating expense savings of $55–$60 million.
Reorganization includes winding down the STARGAZE Phase 2 study in Graft-versus-Host Disease to concentrate resources on apraglutide.
Commercial strategy for apraglutide targets a smaller, specialized prescriber base, focusing on academic centers and patient hub services.
Leadership changes include Greg Martini as SVP, CFO, and Tammi Gaskins as SVP, Chief Commercial Officer.
Apraglutide Development and Data
Rolling NDA submission for apraglutide includes new long-term extension data, with 27 patients achieving enteral autonomy and increased rates of weaning off parenteral support.
Ongoing constructive dialogue with FDA, leveraging fast-track designation to optimize submission and labeling.
Launch planning for apraglutide is underway, emphasizing a robust patient hub service model.
Financial Guidance and Performance
FY2025 guidance: LINZESS U.S. net sales of $800–$850 million, total revenue of $260–$290 million, and adjusted EBITDA over $85 million, with a $40–$45 million net benefit from reorganization.
High single-digit prescription growth for LINZESS is expected, but more than offset by price erosion from Medicare Part D redesign and Medicaid AMP cap repeal.
Adjusted EBITDA definition updated to exclude stock-based compensation starting Q1 2025.
R&D spend anticipated to decline slightly in 2025 due to winding down of certain operations and completion of apraglutide phase III.
Latest events from Ironwood Pharmaceuticals
- LINZESS growth lifted FY 2026 guidance as record EBITDA and apraglutide trial progress advanced.IRWD
Q3 2026 - LINZESS growth supports 2024 targets despite a $1.095B acquisition charge.IRWD
Q4 2023 - Turnaround year with robust growth, LINZESS resurgence, and advancing apraglutide toward 2029 NDA.IRWD
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 net sales surged 44% as guidance rose, debt was repaid, and pipeline advanced.IRWD
Q2 2026 - Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead.IRWD
Jefferies Global Healthcare Conference 2026 - LINZESS U.S. net sales soared 97% year-over-year, fueling robust revenue and profit growth.IRWD
Q1 2026 - Board recommends voting for all proposals, including equity plan amendment and auditor ratification.IRWD
Proxy filing - Key votes include director elections, executive pay, equity plan expansion, and auditor ratification.IRWD
Proxy filing - 2026 guidance targets $1.125B–$1.175B LINZESS U.S. net sales and >$300M adjusted EBITDA.IRWD
Q4 2025 - LINZESS demand grew 13% in Q3 2024, but net sales fell 19% amid pricing headwinds.IRWD
Q3 2024